Treatment of PBMC from COVID-19 patients with fatostatin A (an SREBP-2 processing inhibitor) and SN50 (an NF-κB signaling inhibitor) suppress the production of pro-inflammatory TNF-α and IL-1β. Here, SREBF2 is linked to COVID-19.